IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens
| Autor: | Alexandra F, Santos, Louisa K, James, Henry T, Bahnson, Mohammed H, Shamji, Natália C, Couto-Francisco, Sabita, Islam, Sally, Houghton, Andrew T, Clark, Alick, Stephens, Victor, Turcanu, Stephen R, Durham, Hannah J, Gould, Gideon, Lack |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Arachis PA Peanut allergy mast cells basophil POIT Peanut oral immunotherapy Antibody Specificity Immune Tolerance Ara h 2 Humans Peanut Hypersensitivity Child PS Peanut-sensitized but tolerant IgG4 tolerance HSA Human serum albumin fungi food and beverages peanut allergy SPT Skin prick test Allergens Antigens Plant Immunoglobulin E IgE inhibition Basophils blocking antibodies basophil activation test P-sIgG4 Peanut-specific IgG4 Child Preschool Immunoglobulin G Female peanut Food Drug Insect Sting Allergy and Anaphylaxis P-sIgE Peanut-specific IgE NA Non–peanut-sensitized nonallergic |
| Zdroj: | The Journal of Allergy and Clinical Immunology |
| ISSN: | 1097-6825 |
| Popis: | Background Most children with detectable peanut-specific IgE (P-sIgE) are not allergic to peanut. We addressed 2 non–mutually exclusive hypotheses for the discrepancy between allergy and sensitization: (1) differences in P-sIgE levels between children with peanut allergy (PA) and peanut-sensitized but tolerant (PS) children and (2) the presence of an IgE inhibitor, such as peanut-specific IgG4 (P-sIgG4), in PS patients. Methods Two hundred twenty-eight children (108 patients with PA, 77 PS patients, and 43 nonsensitized nonallergic subjects) were studied. Levels of specific IgE and IgG4 to peanut and its components were determined. IgE-stripped basophils or a mast cell line were used in passive sensitization activation and inhibition assays. Plasma of PS subjects and patients submitted to peanut oral immunotherapy (POIT) were depleted of IgG4 and retested in inhibition assays. Results Basophils and mast cells sensitized with plasma from patients with PA but not PS patients showed dose-dependent activation in response to peanut. Levels of sIgE to peanut and its components could only partially explain differences in clinical reactivity between patients with PA and PS patients. P-sIgG4 levels (P = .023) and P-sIgG4/P-sIgE (P < .001), Ara h 1–sIgG4/Ara h 1–sIgE (P = .050), Ara h 2–sIgG4/Ara h 2–sIgE (P = .004), and Ara h 3–sIgG4/Ara h 3–sIgE (P = .016) ratios were greater in PS children compared with those in children with PA. Peanut-induced activation was inhibited in the presence of plasma from PS children with detectable P-sIgG4 levels and POIT but not from nonsensitized nonallergic children. Depletion of IgG4 from plasma of children with PS (and POIT) sensitized to Ara h 1 to Ara h 3 partially restored peanut-induced mast cell activation (P = .007). Conclusions Differences in sIgE levels and allergen specificity could not justify the clinical phenotype in all children with PA and PS children. Blocking IgG4 antibodies provide an additional explanation for the absence of clinical reactivity in PS patients sensitized to major peanut allergens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect